Aeterna Zentaris
AEZS
NZ$9.60
Share price
2.14%
Change (1 day)
2.80%
Change (1 year)
Categories
P/S ratio for Aeterna Zentaris (AEZS)
P/S ratio as of July 2025 (TTM): 2.77
According to Aeterna Zentaris's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.6677. At the end of 2024 the company had a P/S ratio of 2.11.
P/S ratio history for Aeterna Zentaris from 2001 to 2024
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2024 | 2.11 | 26.84% |
| 2023 | 1.67 | 20.42% |
| 2022 | 1.38 | -65.45% |
| 2021 | 4.00 | 30.19% |
| 2020 | 3.07 | 26.27% |
| 2019 | 2.43 | -68.1% |
| 2018 | 7.63 | 52.73% |
| 2017 | 5.00 | -6.47% |
| 2016 | 5.34 | -27.38% |
| 2015 | 7.36 | 32.54% |
| 2014 | 5.55 | -47.5% |
| 2013 | 10.6 | -10.14% |
| 2012 | 11.8 | -56.41% |
| 2011 | 27.0 | 2.64% |
| 2010 | 26.3 | 73.24% |
| 2009 | 15.2 | 96.95% |
| 2008 | 7.71 | -70.79% |
| 2007 | 26.4 | -69.8% |
| 2006 | 87.4 | -39.54% |
| 2005 | 144 | -37.89% |
| 2004 | 233 | 90.42% |
| 2003 | 122 | -49.24% |
| 2002 | 241 | -42.98% |
| 2001 | 422 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Spectrum Pharmaceuticals
SPPI | 8.22 | 196.53% | 🇺🇸 USA |
 Novartis NVS | 4.31 | 55.40% | 🇨🇭 Switzerland |
 Bristol-Myers Squibb BMY | 2.00 | -27.75% | 🇺🇸 USA |
 Sanofi SNY | 2.56 | -7.53% | 🇫🇷 France |
 Halozyme Therapeutics HALO | 6.71 | 142.17% | 🇺🇸 USA |